A5065848199- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- DNA and Nucleic Acid Chemistry
- Advanced biosensing and bioanalysis techniques
- RNA Interference and Gene Delivery
- Glycosylation and Glycoproteins Research
- Radiopharmaceutical Chemistry and Applications
- Cancer Treatment and Pharmacology
University of Maryland, Baltimore
2023
Center for Drug Evaluation and Research
2021-2022
United States Food and Drug Administration
2021-2022
Both EGFR and VEGFR2 frequently overexpress in TNBC cooperate with each other autocrine paracrine manner to enhance tumor growth angiogenesis. Therapeutic mAbs targeting (cetuximab) (ramucirumab) are approved by FDA for numerous cancer indications, but none of them treat breast cancers. cells secrete VEGF-A, which mediates angiogenesis on endothelial a fashion, as well promotes cell manner. To disrupt autocrine/paracrine loop models addition mediating anti-EGFR signaling anti-VEGFR2...
We generated two IgG1-like bispecific antibodies (BsAbs) with different molecular formats, symmetrical DVD-Ig and asymmetrical knob-in-hole (KIH), targeting the same antigens, EGFR PD-L1 (designated as anti-EGFR/PD-L1). performed physiochemical biological characterization of these formats anti-EGFR/PD-L1 BsAbs compared some key quality attributes activities BsAbs. Physiochemical binding data demonstrated that both bound PD-L1. However, affinity KIH format was weaker than in Biacore assays....
Abstract Triple-negative breast cancer (TNBC) accounts for approximately 10-20% of all diagnosed cancer. Both epidermal growth factor receptor (EGFR) and vascular endothelial 2 (VEGFR2) frequently overexpress in TNBC cooperate with each other autocrine paracrine manner to enhance tumor angiogenesis. Therapeutic mAbs targeting EGFR (cetuximab) VEGFR2 (ramucirumab) are approved by FDA numerous indications, but none them treat cancers. cells secrete VEGF-A, which mediate angiogenesis on a...